Cambridge-based Magenta Therapeutics entered a non-exclusive research and clinical collaboration agreement with Beam Therapeutics.
CRISPR Therapeutics and Vertex Pharmaceuticals announced positive interim data from the first patients in the companies’ Phase I/II clinical trials of the CRISPR/Cas9 gene-editing therapy CTX001.
Three Small CRISPR Biotechs That Could Cure 10,000 Diseases
Blood Diseases, Cancer, Collaborations, CRISPR/Cas9, Diseases, DNA, Eye Diseases, FDA, Gene Editing, Genetic Disorders, Genomics, Hematopoietic Stem Cells, Herpes Simplex Virus, Hunter Syndrome, Immune Cells, Inflammatory Disorders, J.P. Morgan Healthcare Conference, Liver Disease, Lung Disease, Muscle Disease, R&D, Sickle Cell Disease, Thalassemia, Transthyretin (TTR) Amyloidosis, Viral Infections, World Health OrganizationInvestor’s Business Daily looked at three small biotech companies that appear to be leading the CRISPR race.